Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Gastrointestinal tumours, colorectal

404MO - Clinical relevance of MIR27A rs895819 polymorphism and its interaction with DPYD variants for predicting grade 4-5 fluoropyrimidine (FP) toxicity (tox) in the FUSAFE individual patient data meta-analysis (IPD-MA)

Date

18 Sep 2020

Session

Mini Oral - Gastrointestinal tumours, colorectal

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Marie-Christine Etienne-Grimaldi

Citation

Annals of Oncology (2020) 31 (suppl_4): S409-S461. 10.1016/annonc/annonc270

Authors

M. Etienne-Grimaldi1, N. Cozic2, V. Boige3, J. Boyer4, D. Meulendijks5, C. Palles6, U. Zanger7, C. Largiadèr8, R.B. Diasio9, B. Jennings10, J. Taieb11, M. Deenen12, T. Marinaki13, E. Gross14, A. van Kuilenburg15, F. Thomas-Jean16, M. Loriot17, J. Pignon18, G. Le Teuff18

Author affiliations

  • 1 Oncopharmacology Laboratory, Centre Antoine Lacassagne, 06189 - Nice/FR
  • 2 Biostatistics And Epidemiology, Gustave-Roussy Cancer Campus, 94805 - Villejuif/FR
  • 3 Digestive Oncology, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 4 Biochemistry And Biomolecular Department, CHU de Nîmes, Nîmes/FR
  • 5 Global Medicines Development, AstraZeneca, Cambridge/GB
  • 6 Institute Of Cancer And Genomic Sciences, University of Birmingham, Birmingham/GB
  • 7 Molecular And Cell Biology Department, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart/DE
  • 8 Department Of Clinical Chemistry, Inselspital Bern University Hospital, Bern/CH
  • 9 Department Of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic Cancer Center, Rochester/US
  • 10 Molecular Genetics Department, Norwich University Hospital, Norwich/GB
  • 11 Gastroenterology And Digestive Oncology Department, Hopital European George Pompidou, 75015 - Paris/FR
  • 12 Clinical Pharmacy, Catharina Hospital Eindhoven, 5602 ZA - Eindhoven/NL
  • 13 Purine Research Laboratory, St Thomas' Hospital, London/GB
  • 14 Department Of Gynecology, Munich University Hospital, Munich/DE
  • 15 Laboratory Of Genetic Metabolic Diseases, Amsterdam University Medical Center, Amsterdam/NL
  • 16 Oncopharmacology Laboratory, IUCT-Oncopole - Institut Claudius Regaud, Toulouse/FR
  • 17 Clinical Chemistry Department, Hôpital Européen Georges Pompidou, Paris/FR
  • 18 Biostatistics And Epidemiology, Gustave-Roussy Cancer Campus, Villejuif/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 404MO

Background

Dihydropyrimidine dehydrogenase (DPD) deficiency is the main cause of severe FP-tox. DPD expression is regulated at post-transcriptional level by miR-27a. MIR27A rs895819A>G has been associated with significant increased grade (G) ≥3 FP-tox only in patients (pts) carrying a deleterious DPYD variant (*2A/D949V/*13/HapB3). French GPCO-UNICANCER and RNPGx groups initiated the FUSAFE IPD-MA to develop predictive models of FP-tox, allowing to test whether MIR27A rs895819 improves the predictive value of DPYD variants.

Methods

Eligibility criteria included unbiased recruitment of Caucasian pts without FP dose adjustment based on DPD status. Main endpoint was hematological or digestive G4-5 FP-tox at 12 weeks. A clinical logistic regression model including age, sex, body mass index, FP administration (bolus±continuous vs continuous/p.o.) and associated anticancer drug (AAD) was first developed. Combined DPYD variants *2A/D949V/*13 with or without HapB3 (at least one mutated allele) and MIR27A rs895819 (dominant coding) were further included in this model, along with DPYD x MIR27A interaction.

Results

Full clinical data, MIR27A, and DPYD variants were assessable in 2724 pts (5 studies): 71% colorectal cancer, 41% metastatic, 95% FP-naïve, 31% 5FU, 55% AAD. MIR27A rs895819G was carried by 53.4% of pts (9.7% homozygotes) and 1.5% of pts (N=41) carried at least one *2A/D949V/*13 DPYD variant. G4-5 FP-tox was 4.0%. Adjusted Odds Ratio were 6.9 [95%CI 3.0-16.0] for DPYD combined variants *2A/D949V/*13, and 1.3 [95%CI 0.9-1.9] for MIR27A rs895819, with no DPYD x MIR27A statistical interaction (p=0.99). Results on MIR27A and its interaction with DPYD variants were similar when considering G3-4-5 tox at cycle 1, or HapB3.

Conclusions

This IPD-MA on MIR27A and DPYD variants, including the largest series of pts published so far, do not confirm the previously published relevance of MIR27A rs895819 for toxicity risk stratification in patients carrying DPYD risk variants. The ongoing FUSAFE-2 project including sequencing of DPYD and MIR genes may provide new insights in FP pharmacogenetics.

Clinical trial identification

CRD 42017058148.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

French Cancer Institute & French Health Ministry (PHRC-K 14-193 \"FUSAFE\") and French Ligue Contre le Cancer.

Disclosure

M-C. Etienne-Grimaldi: Honoraria (self), Travel/Accommodation/Expenses: Amgen. V. Boige: Honoraria (self), Advisory/Consultancy: Bayer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Merck Serono; Honoraria (self): Amgen; Advisory/Consultancy, Travel/Accommodation/Expenses: Sanofi; Travel/Accommodation/Expenses: Daiichi Sankyo; Honoraria (self): Roche; Honoraria (self): MSD; Honoraria (self), Advisory/Consultancy: Ipsen; Advisory/Consultancy: Prestizia; Honoraria (self), Advisory/Consultancy: Eisai. D. Meulendijks: Shareholder/Stockholder/Stock options, Full/Part-time employment: AstraZeneca. C. Palles: Advisory/Consultancy: Oxford Cancer Biomarkers. U. Zanger: Licensing/Royalties: Robert Bosch GmbH. J. Taieb: Advisory/Consultancy: Amgen; Honoraria (self): Lily; Advisory/Consultancy: Sanofi; Honoraria (self): Roche; Advisory/Consultancy: Merk; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self): Celgene; Advisory/Consultancy: Servier; Honoraria (self): Sirtex; Advisory/Consultancy: Pierre Fabre. E. Gross: Licensing/Royalties, Method for predicting treatment response in breast cancer: Patent pending. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.